The Management Board of Sygnis S.A. with its registered office in Gdańsk “the Company” informs that as a result of the review of the accounting books conducted in connection with the preparation of the Company’s financial statements for the year 2023 and the consolidated financial statements of the Sygnis Capital Group for the year 2023, it decided today to make revaluation write-downs in the total: amount of PLN 1,125,915.90, including in particular:

• in the amount of PLN 22,450.00 on 449 shares of Albireo Biomedical sp. z o.o. and in the amount of PLN 16,423.85 of the loan granted to this company, in connection with the placing of this company into liquidation;
• in the amount of PLN 95,876.51 with regard to the write-off of 1/7 one seventh of the value of shares held in Zmorph SA, due to ongoing optimisation work at this company, which is implementing a recovery plan to achieve profitability;
• in the amount of 201 050.00 and 790 115.54 regarding the write-down of receivables of 3D Printers Sp. z o.o. and Zmorph SA.

The above-mentioned write-downs will have a direct impact on the reduction of the Company’s and the Group’s financial result.

As a result of the write-down of receivables, as a consequence of the construction of the acquisition of Zmorph S.A., the balance sheet total of the Company and the Group decreased by the amount of 6,838,521.24 . Which consists of the amount of 1,243,132.12 the value of the entire receivables of 3D Printers sp. z o.o. and 5,595,389.12 – the value of part of the receivables of Zmorph S.A.

At the same time, the Management Board indicates that the creation of the write-downs in question does not affect the liquidity and operational situation of the Company and the Capital Group formed by it.